Literature DB >> 25530367

Midterm efficacy and complications of readjustable midurethral sling (Remeex system) in female stress urinary incontinence with recurrence or intrinsic sphincter deficiency.

Bong Hee Park1, Joon Chul Kim2, Hyun Woo Kim3, Young Ho Kim4, Jong Bo Choi5, Dong Hwan Lee6.   

Abstract

OBJECTIVE: To evaluate the efficacy, complications, and managements of the readjustable midurethral sling (Remeex system) for the treatment of recurrent stress urinary incontinence (SUI) after previous anti-incontinence surgeries or intrinsic sphincter deficiency (ISD).
METHODS: Between March 2008 and February 2012, 102 women, who presented with previous failed surgery or ISD, were treated with the Remeex system at 4 different institutions. We retrospectively reviewed medical history, physical examination, urodynamic study, postvoiding residual volume, and/or 1-hour pad test of the patients. Surgical outcomes were evaluated using the Severity Index for Urinary Incontinence. The degree of patient satisfaction was assessed, and all complications were classified according to the modified Clavien classification system.
RESULTS: After a mean follow-up of 27.6 months (range, 14-56 months), 91 patients (89.2%) were cured and 6 patients (5.9%) were improved. The patient's satisfaction rate was 87.2% (89 of 102 patients). Overall, 41 patients (40.2%) experienced 53 complications; 15 patients (14.7%) presented de novo urgency, which was properly managed with anticholinergics, and 14 patients (13.7%) underwent delayed sling readjustment for recurrent SUI (n = 13) and urinary retention (n = 1) during follow-up. Among 6 patients (5.9%) with wound infection, 4 patients were successfully treated by daily dressing with antibiotics, and 2 patients underwent removal of the Remeex system owing to intractable infection. Most complications were classified as grade 1 (54.8%) or 2 (15.1%) and were successfully treated with minimal conservative measures.
CONCLUSION: The Remeex system is a valuable adjunct for recurrent SUI after previous anti-incontinence surgeries or ISD, considering most complications are Clavien grade I or II.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2015        PMID: 25530367     DOI: 10.1016/j.urology.2014.10.003

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  6 in total

1.  Adjustable transobturator sling for the treatment of primary stress urinary incontinence.

Authors:  Dmitry Shkarupa; Nikita Kubin; Olga Staroseltseva; Ekaterina Shapovalova
Journal:  Int Urogynecol J       Date:  2017-11-25       Impact factor: 2.894

2.  Effectiveness of the Remeex system™ in Colombian women with recurrent stress urinary incontinence or intrinsic sphincter deficiency.

Authors:  Mauricio Plata; Daniela Robledo; Alejandra Bravo-Balado; Juan Carlos Castaño; Catalina Osorio; Milton Salazar; Juan Guillermo Velásquez; Carlos Gustavo Trujillo; Juan Ignacio Caicedo; Juan Guillermo Cataño
Journal:  Int Urogynecol J       Date:  2018-03-03       Impact factor: 2.894

3.  A modified Altis® mid-urethral sling that allows immediate post-operative adjustment: experience in 197 patients.

Authors:  Brett J Friedman; Jennifer Nguyen; Annah Vollstedt; Mireya Diaz; Ly Hoang Roberts; Larry T Sirls
Journal:  Int Urol Nephrol       Date:  2022-01-04       Impact factor: 2.370

4.  Efficacy and safety of a readjustable midurethral sling (Remeex system) for stress urinary incontinence with female voiding dysfunction.

Authors:  Jae-Wook Chung; Eun Sang Yoo
Journal:  Investig Clin Urol       Date:  2017-01-25

5.  Readjustable midurethral sling (REMEEX system) in obese women.

Authors:  Woong Bin Kim; Sang Wook Lee; Kwang Woo Lee; Jun Mo Kim; Young Ho Kim; Min Eui Kim
Journal:  Investig Clin Urol       Date:  2019-09-23

6.  Predictors for De Novo Overactive Bladder after Readjustable Mid-Urethral Sling Procedure in Women with Stress Urinary Incontinence due to Intrinsic Sphincter Deficiency.

Authors:  Joo Hyun No; Kyung Hwa Choi; Dae Keun Kim; Tae Heon Kim; Seung Ryeol Lee
Journal:  Biomed Res Int       Date:  2018-11-26       Impact factor: 3.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.